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Background
We recently characterized several new broadly neutralizing
monoclonal antibodies (bnMAbs) remarkable for their in
vitro potency. A number of these bnMAbs are almost 10
fold more potent than previously isolated bnMAbs such as
PG9 and VRC01 and hundred fold more potent than older
prototype bnMAbs such as 2G12 and b12. Of the new
antibodies, PGT121 is one of the most broad and potent,
and recognizes a glycan-dependent epitope. Based on in
vitro neutralization potency, we speculated that PGT121
may be protective in vivo at serum concentrations below
those previously determined for other broadly neutralizing
anti-HIV antibodies.
Methods
The neutralization potency of PGT121 against SHIV
SF162P3 was evaluated using a TZMbl-based neutralization
assay. To evaluate the protective potency of PGT121 in
vivo, we then designed a protection study in rhesus maca-
ques. Animals were administered intravenously with 3 dif-
ferent doses of antibody (5 mg/kg, 1 mg/kg or 0.2 mg/kg)
24 hours before being vaginally challenged with a single
high dose of SHIV SF162P3 (300 TCID50). Serum levels of
antibody and viral loads were determined throughout the
study.
Results
PGT121 potently neutralizes SHIV SF162P3 with an IC50
of about 0.005 µg/ml. Preliminary data suggest that an
administered dose of PGT121 at 1 mg/kg is sufficient to
induce sterilizing immunity against a single high dose
vaginal challenge of SHIV SF162P3. A lower 0.2 mg/kg
dose appears to be partially protective.
Conclusion
PGT121 is one of the most broad and potent neutralizing
antibodies isolated to date. Here, we provide evidence
that in vivo protection by PGT121 correlates with the
high in vitro potency of the antibody. PGT121 can thus
mediate sterilizing immunity at concentrations that are
significantly lower than previously observed from passive
protection studies with bnMAbs and may be readily
achievable through vaccination.
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